FilingReader Intelligence
Sino Biopharmaceutical gets China approval for cancer drug trial
August 7, 2025 at 01:59 PM UTC•By FilingReader AI
Sino Biopharmaceutical announced China's drug regulator approved Phase II clinical trials of LM-24C5, a bispecific antibody targeting solid tumors.
The drug, developed by wholly-owned subsidiary LaNova Medicines, is designed to activate immune cells against cancer. It's currently in Phase I/II trials in the United States.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1177•Hong Kong Exchange
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime